These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 38110554)
1. Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice. Brennan MS; Brinkmann K; Romero Sola G; Healey G; Gibson L; Gangoda L; Potts MA; Lieschke E; Wilcox S; Strasser A; Herold MJ; Janic A Cell Death Differ; 2024 Feb; 31(2):159-169. PubMed ID: 38110554 [TBL] [Abstract][Full Text] [Related]
2. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Valente LJ; Gray DH; Michalak EM; Pinon-Hofbauer J; Egle A; Scott CL; Janic A; Strasser A Cell Rep; 2013 May; 3(5):1339-45. PubMed ID: 23665218 [TBL] [Abstract][Full Text] [Related]
3. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53. Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149 [TBL] [Abstract][Full Text] [Related]
4. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Bieging-Rolett KT; Kaiser AM; Morgens DW; Boutelle AM; Seoane JA; Van Nostrand EL; Zhu C; Houlihan SL; Mello SS; Yee BA; McClendon J; Pierce SE; Winters IP; Wang M; Connolly AJ; Lowe SW; Curtis C; Yeo GW; Winslow MM; Bassik MC; Attardi LD Mol Cell; 2020 Nov; 80(3):452-469.e9. PubMed ID: 33157015 [TBL] [Abstract][Full Text] [Related]
5. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333 [TBL] [Abstract][Full Text] [Related]
6. Mouse models to investigate in situ cell fate decisions induced by p53. Lieschke E; Thomas AF; Kueh A; Atkin-Smith GK; Baldoni PL; La Marca JE; Young S; Huang AS; Ross AM; Whelan L; Kaloni D; Tai L; Smyth GK; Herold MJ; Hawkins ED; Strasser A; Kelly GL EMBO J; 2024 Oct; 43(19):4406-4436. PubMed ID: 39160273 [TBL] [Abstract][Full Text] [Related]
7. Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance. Belle JI; Petrov JC; Langlais D; Robert F; Cencic R; Shen S; Pelletier J; Gros P; Nijnik A Cell Death Differ; 2016 May; 23(5):759-75. PubMed ID: 26768662 [TBL] [Abstract][Full Text] [Related]
8. Puma and p21 represent cooperating checkpoints limiting self-renewal and chromosomal instability of somatic stem cells in response to telomere dysfunction. Sperka T; Song Z; Morita Y; Nalapareddy K; Guachalla LM; Lechel A; Begus-Nahrmann Y; Burkhalter MD; Mach M; Schlaudraff F; Liss B; Ju Z; Speicher MR; Rudolph KL Nat Cell Biol; 2011 Dec; 14(1):73-9. PubMed ID: 22138576 [TBL] [Abstract][Full Text] [Related]
9. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Thomas AF; Kelly GL; Strasser A Cell Death Differ; 2022 May; 29(5):961-971. PubMed ID: 35396345 [TBL] [Abstract][Full Text] [Related]
10. Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression. Indeglia A; Murphy ME Crit Rev Biochem Mol Biol; 2024; 59(1-2):128-138. PubMed ID: 38661126 [No Abstract] [Full Text] [Related]
11. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937 [TBL] [Abstract][Full Text] [Related]
12. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Kerr JB; Hutt KJ; Michalak EM; Cook M; Vandenberg CJ; Liew SH; Bouillet P; Mills A; Scott CL; Findlay JK; Strasser A Mol Cell; 2012 Nov; 48(3):343-52. PubMed ID: 23000175 [TBL] [Abstract][Full Text] [Related]
13. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933 [TBL] [Abstract][Full Text] [Related]
14. p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Thakur VS; Ruhul Amin AR; Paul RK; Gupta K; Hastak K; Agarwal MK; Jackson MW; Wald DN; Mukhtar H; Agarwal ML Cancer Lett; 2010 Oct; 296(2):225-32. PubMed ID: 20444544 [TBL] [Abstract][Full Text] [Related]
15. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Michalak EM; Villunger A; Adams JM; Strasser A Cell Death Differ; 2008 Jun; 15(6):1019-29. PubMed ID: 18259198 [TBL] [Abstract][Full Text] [Related]
16. iNOS/NO is required for IRF1 activation in response to liver ischemia-reperfusion in mice. Du Q; Luo J; Yang MQ; Liu Q; Heres C; Yan YH; Stolz D; Geller DA Mol Med; 2020 Jun; 26(1):56. PubMed ID: 32517688 [TBL] [Abstract][Full Text] [Related]
18. Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation. Jabbour AM; Daunt CP; Green BD; Vogel S; Gordon L; Lee RS; Silke N; Pearson RB; Vandenberg CJ; Kelly PN; Nutt SL; Strasser A; Borner C; Ekert PG Blood; 2010 Jan; 115(2):344-52. PubMed ID: 19965665 [TBL] [Abstract][Full Text] [Related]
19. The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma. Muys BR; Anastasakis DG; Claypool D; Pongor L; Li XL; Grammatikakis I; Liu M; Wang X; Prasanth KV; Aladjem MI; Lal A; Hafner M Genes Dev; 2021 Jan; 35(1-2):102-116. PubMed ID: 33334821 [TBL] [Abstract][Full Text] [Related]
20. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice. Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]